MAXPHARMA
Timeline
42 events since 2000Board
Capital
Filings
Financial
Establishments
Address
200020052010201520202025
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 30 days before the deadline
2025
Back to profit net €15,264 The net result is €15,264, after 3 loss-making years.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0471830863
Annual accounts 2024 filed PDFfull format · 7 days before the deadline
Registered office moved from Wavre to EtterbeekNew registered office: chaussée de Wavre n°736, 1040 ETTERBEEK · Previous registered office: rue des Templiers 73, 1301 Wavre · Resignation: (managing director) · General meeting of 01-01-20256 points ▸
- General meeting, 01-01-2025
- Director resignation, (managing director)
- Permanent representative,
- Director appointment, (managing director)
- Permanent representative,
- Registered-office move, chaussée de Wavre n°736, 1040 ETTERBEEK
2024
Weakest financial year net -€25,208 The net result drops to -€25,208, the lowest from 2006 to 2025. It recovers the following year.
Annual accounts 2022 filed PDFabbreviated format · 452 days late
Annual accounts 2023 filed PDFfull format · 23 days late
2022
Annual accounts 2021 filed PDFfull format · 18 days before the deadline
New managing director appointed, resigned · Permanent representative: · Director discharge: · General meeting of 10-02-20225 points ▸
- General meeting, 10-02-2022
- Director resignation, (managing director)
- Director discharge,
- Director appointment, (managing director)
- Permanent representative,
- The deed holds 1 more point.
2021
Annual accounts 2020 filed PDFfull format · 31 days late
Resignation: (managing director)General meeting of 07-05-20212 points ▸
- General meeting, 07-05-2021
- Director resignation, (managing director)
2020
Annual accounts 2019 filed PDFfull format · 31 days before the deadline
2019
Liquidity more than triples current ratio 1.84 The current ratio rises from 0.46 to 1.84.
Annual accounts 2018 filed PDFmicro format · 29 days late
Merger: GEHELULE takes over MAXPHARMACompany renamed from GEHELULE to MAXPHARMA · Resignation: (manager) · The company holds all the shares of MAXPHARMA · General meeting of 10-01-20197 points ▸
- General meeting, 10-01-2019, mentioned twice in the deed
- The company holds all the shares of MAXPHARMA
- Accounting effect, 01-01-2019
- Name change, MAXPHARMA
- Director resignation, (manager)
- Director discharge, (gérante de la société absorbée)
- Power of attorney,
- The deed holds 9 more points.
2018
Highest result from 2006 to 2025 net €82,902 ▲612% The operating result of €111,401 and the net result of €82,902 are both a record.
Merger proposal: GEHELULE takes over MAXPHARMAThe company holds all the shares of MAXPHARMA2 points ▸
- Accounting effect, 01-01-2019
- The company holds all the shares of MAXPHARMA
- The deed holds 3 more points.
Annual accounts 2017 filed PDFfull format · 13 days late
Reappointments: (managing director) and (managing director)General meeting of 06-06-20186 points ▸
- General meeting, 06-06-2018
- Director reappointment,
- Director reappointment,
- Board meeting, 06-06-2018
- Director reappointment, (managing director)
- Director reappointment, (managing director)
- The deed holds 1 more point.
Capital increaseCapital from €160,973.38 to €61,973.38 · Capital from €61,973.38 to €160,973.38, 396 new shares · Founding capital of BEF 2.500.000, 250 shares · General meeting of 22-12-20176 points ▸
- General meeting, 22-12-2017
- Incorporation, 05-05-2000
- Capital decrease, €99,000
- Amendment of the articles, article 5
- Founding capital, BEF 2.500.000, 250 shares
- Capital increase, €99,000
2017
Annual accounts 2016 filed PDFfull format · 25 days before the deadline
2016
Annual accounts 2015 filed PDFfull format · 30 days late
2015
Annual accounts 2014 filed PDFfull format · 24 days late
2014
Equity above €200,000 equity €203,644 ▲6.5% Equity rises from €191,186 to €203,644.
Annual accounts 2013 filed PDFfull format · 46 days late
2013
Annual accounts 2012 filed PDFfull format · 29 days late
2012
Annual accounts 2011 filed PDFfull format · 34 days before the deadline
2011
Annual accounts 2010 filed PDFfull format · 31 days late
2010
Equity above €150,000 equity €167,728 ▲17.5% With a profit in every financial year since 2006, equity grows to €167,728.
Annual accounts 2009 filed PDFfull format · 24 days late
2009
Annual accounts 2008 filed PDFfull format · 28 days late
2008
Annual accounts 2007 filed PDFfull format · 26 days late
2007
Annual accounts 2006 filed PDFfull format · 42 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2000
Incorporation published on 17-05-2000
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
On 5 May 2000, MAXPHARMA was incorporated.1 A capital increase in 2018 brought the capital to €160,973.2 MAXPHARMA was merged into the company in 2018.3 In 2025 the registered office moved to Etterbeek.4 Total assets went from €425,859 in 2018 to €426,986 in 2025 and headcount from 2.1 full-time equivalents in 2019 to 1.9 in 2025.5